These findings are important, since they are likely to indicate continuing cellular damage. It should be emphasized that any cause of major cellular necrosis might produce such effects and they should not be considered as specific indicators of rejection. They are of clinical significance, for they will produce a tendency to thrombosis, particularly at sites of vascular damage or of stasis in blood flow. Major vessels may be concerned, but thrombi were also found in the small vessels of the lung and gastrointestinal tract at necropsy in three patients. If (Brain et al., 1962 ; Baker et al., 1968 Introduction The criteria for the acceptability of a hypnotic should be demanding. They obviously include a reasonable certainty that adequate sleep will be induced, but lack of confusion or hangover and absence of dependence, drug rashes, and other adverse effects are equally important. In addition the rapid rise in the incidence of self-poisoning with sedative drugs (Scottish Health Services Council, 1968) makes it highly desirable to have available an effective hypnotic which is safe in overdose. At first sight such an aim is a pharmacological paradox, as a drug which in therapeutic doses will effectively induce sleep is unlikely at the same time to be safe in overdosage. This is certainly true of barbiturates (Setter et al., 1966) , methaqualone (Matthew et al., 1968) , and glutethimide (Linton, 1966 In the 10 patients who had taken the greatest number of tablets the presence of nitrazepam or its metabolites in blood or urine was confirmed (Tompsett, 1968) . The patients comprised three males and 24 females between the ages of 12 and 82 years. The number of tablets ingested and the level of consciousness of these patients on admission to hospital are shown in Table I . Twenty-five patients were fully conscious throughout; the duration of drowsiness in the remaining two was less than 12 hours. 
Therapeutic Efficacy of Nitrazepam
Externally identical tablets of nitrazepam 5 mg., butobarbitone 100 mg., and placebo were prepared for a doubleblind trial in a balanced design. As there are six possible orders in which the drugs could be prescribed, patients were allocated to one of these on entering the trial. Each patient was given each substance for a week in a dose of two tablets nightly. The trial continued until three patients in each order had completed it satisfactorily, thus providing full information on 18 patients.
Thirty-four patients who were willing to participate in the trial were selected from the general medical wards ; each was thought likely to be in the ward for three weeks and to be sufficiently co-operative to supply the desired information. Eleven patients were discharged before completing the trial and five others were withdrawn (see below) ; their results have been discarded.
The Quality of Sleep (Patients' Scores).-Six per cent. of these scores were also missing, and as the distribution of those obtained was markedly skew towards the " perfect " this was adjusted to normality by arcsin transformation before analysis (Snedecor and Cochran, 1967) . The mean nightly score for the 18 patients on each drug is also shown in Table II . Analysis of variance of the scores showed that the quality of sleep was very significantly better when the patients were having nitrazepam or butobarbitone than when on placebo. Again there was no significant difference between nitrazepam and butobarbitone. The main effect of " weeks " in the analysis of variance was also significant (F2 333= 10-3; P<0 001).
The mean score for each week, irrespective of the drug taken, showed significant improvement (P=0 001) as the patients progressed in the trial (week 1, 0-676 ; week 2, 0-758 ; week 3, 0 806).
Association Between Scores.-The product-moment correlation coefficient between the patients' and nurses' scores was + 0501 (P = 0001). Correlation coefficients were also calculated for each patient separately ; 17 were positive, ranging up to + 0894 ; 12 of these were significant at least at the P=005 level of probability.
Dream Recall.-There was no noticeable difference in the number of patients with dream recall in the morning or in the vividness of dreams while having nitrazepam (compared with the week before or after nitrazepam).
Withdrawals from Trial.-Only one of the five patients withdrawn from the trial was removed because of possible toxic effects of the drug. This patient was a 67-year-old woman suffering from pyelonephritis. She (Jordan, 1965) . Nor has this drug shown any incompatibility when used with other drugs in the treatment of epilepsy (Kryspin-Exner, 1966) , thyrotoxicosis, cardiac failure, hypertension (Maibach, 1965) , and diabetes mellitus (Wyss and Mader, 1965) . Dependence on, or addiction to, nitrazepam has not been observed (Franke, 1965 ; Bethune et al., 1966) , nor has there been any report of delirium or epileptic seizures on withdrawal of the drug such as may complicate the withdrawal of other hypnotics (Glatt, 1968 It is therefore evident that nitrazepam is a hypnotic which, tablet for tablet, is unsurpassed as yet in safety. This element of safety would, however, be valueless if it were not also shown that the drug had a hypnotic effect as adequate as a barbiturate.
Many methods, including use of activity beds and continuous E.E.G. monitoring, are available for the assessment of hypnotic drugs. Nevertheless, as insomnia is a subjective state, a feeling beyond the observation of mere indicants, the paradigm should surely be the personal report of the patient. The language offered to the patients in this trial for communication of their feelings is known to be reliable and valid (Aitken, 1969) .
The clinical trial clearly showed that nitrazepam was superior to a placebo as a hypnotic drug, and that it was as effective as butobarbitone. There was consistency between the patients' reports on the quality of sleep and the nurses' assessments of the duration of sleep. The results are similar to those of another trial with a similar method of analysis comparing nitrazepam and sodium amylobarbitone in psychiatric patients (Davies and Levine, 1967) .
We conclude that nitrazepam is an effective hypnotic which is safe in overdosage.
